Centralized Pregnancy Registries May Benefit Small Firms Most - FDA
Executive Summary
A centralized pregnancy registry may be most beneficial for smaller pharmaceutical and biotech companies by addressing resource and infrastructure limitations, FDA suggested at a March 29 meeting of the Pregnancy Labeling Subcommittee.
You may also be interested in...
Pregnancy Safety Reporting Reg Will Add Additional Data To Product Labels
Manufacturers will need to work with FDA to incorporate information on drug experience during pregnancy into product labeling, following publication of an upcoming safety reporting regulation from the agency, Office of Drug Evaluation IV Deputy Director Sandra Kweder, MD, said Dec. 4.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011